Under-the-radar Eden Research (EDEN:AIM), whose backers include Livingbridge UK Micro Cap Fund (GB00BV9FYS80) and Artemis Alpha Trust (ATS), looks an attractive...

A price war among exchange-traded fund providers looks imminent as French firm Lyxor has lowered fees on 12 of its products.

The firm says these...

Retailer JD Sports Fashion (JD.) is stepping into the vast US sportswear market through the near-£400m acquisition of NASDAQ-traded footwear seller Finish Line....

Document management and office removals expert Restore (RST:AIM) has made its biggest acquisition to date, paying £88m for TNT’s UK records management operations....

Quixant (QXT:AIM) 410p

Loss to date: -6.3%

Original entry point: Buy at 437.5p, 25 January 2018

Retail investors want full disclosure of fees when buying an investment product but aren’t convinced they’re getting it, according to research from the CFA Institute...

Hopes are growing that talks between the US and China can avert a trade war after the threat of tit-for-tat action last week saw markets...

US -listed Pfizer has been shunned by consumer goods specialist Reckitt Benckiser (RB.) and drugs giant GlaxoSmithKline (GSK) after both firms...

Demand for new homes continues apace but the investment case for the housebuilders is muddied by legitimate concern their margins may have peaked. We believe...

Taptica (TAP:AIM) 369.3p

Loss to date: -17.5%

Original entry price: Buy at 447.5p, 25 January 2018